SCHEMBL933677

SCHEMBL933677

O=C(O)c1ccccc1OCC1CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
KMT2A Q03164 1/20 0.57
PTK2B Q14289 1/20 0.57
KDM4E B2RXH2 6/20 0.56
HTT P42858 2/20 0.56
FAAH O00519 1/20 0.50
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
MRGPRX1 Q96LB2 1/20 0.49
RIPK1 Q13546 1/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 4/20 0.47
ESR1 P03372 1/20 0.47
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
HMGB1 P09429 1/20 0.47
TSHR P16473 1/20 0.47
GGT1 P19440 1/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29055574 0.93 FAAH (0.57) ALDH1A1KMT2APTK2BKDM4EHTT
SCHEMBL3064765 0.93 FAAH (0.54) ALDH1A1KMT2APTK2BKDM4EHTT
SCHEMBL1388095 0.92 FAAH (0.60) ALDH1A1KMT2APTK2BKDM4EHTT
SCHEMBL20476485 0.89 ALDH1A1 (0.50) ALDH1A1KMT2APTK2BKDM4EHTT
SCHEMBL16759161 0.89 ALDH1A1 (0.50) ALDH1A1KMT2APTK2BKDM4EHTT
SCHEMBL27854331 0.88 FAAH (0.51) ALDH1A1KMT2APTK2BKDM4EHTT
SCHEMBL238499 0.87 PTGER1 (0.47) ALDH1A1KMT2APTK2BKDM4EHTT
SCHEMBL27983423 0.85 FAAH (0.52) ALDH1A1KMT2APTK2BKDM4EHTT
SCHEMBL4000543 0.85 ALDH1A1 (0.53) ALDH1A1KMT2AKDM4EHTTFAAH
SCHEMBL17431711 0.84 SLC6A2 (0.50) ALDH1A1KMT2APTK2BKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO claimed
CN-1042534-C Aroyl-urres WYETH JOHN & BROTHER LTD (GB) 1999-03-17 CN claimed
EP-0422846-B1 Aroyl-ureas WYETH JOHN & BROTHER LTD (GB) 1994-02-16 EP claimed
CN-1050875-A AROYL-URRES WYETH JOHN & BROTHER LTD (GB) 1991-04-24 CN claimed
EP-0422846-A2 Aroyl-ureas JOHN WYETH & BROTHER LIMITED (GB) 1991-04-17 EP claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO disclosed
CN-105085429-B Aromatic heterocyclic derivative and application thereof in medicines 广东东阳光药业有限公司 2019-12-10 CN disclosed
WO-2017192304-A1 ARYLCARBOXAMIDES AND USES THEREOF INCEPTION 1, INC. (US) 2017-11-09 WO disclosed
CN-106946848-A It is used as the derivative of the pyridyl alkyl alcohol of 1 phenyl 2 of phosphodiesterase inhibitors 奇斯药制品公司 2017-07-14 CN disclosed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US disclosed
EP-3149002-A1 5-OXA-2-AZABICYCLO[2.2.2]OCTAN-4-YL AND 5-OXA-2-AZABICYCLO[2.2.1]HEPTAN-4-YL DERIVATIVES AS TAAR1 MODULATORS F. Hoffmann-La Roche AG (CH) 2017-04-05 EP disclosed
WO-2006128803-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 WO disclosed
US-20050209241-A1 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. 2005-09-22 US disclosed
CN-1042534-C Aroyl-urres WYETH JOHN & BROTHER LTD (GB) 1999-03-17 CN disclosed
EP-0422846-B1 Aroyl-ureas WYETH JOHN & BROTHER LTD (GB) 1994-02-16 EP disclosed
CN-1050875-A AROYL-URRES WYETH JOHN & BROTHER LTD (GB) 1991-04-24 CN disclosed
EP-0422846-A2 Aroyl-ureas JOHN WYETH & BROTHER LIMITED (GB) 1991-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209241-A1 Benzoyl-piperazine derivatives SLC1A2, SLC18A2, SLC6A7 ALDH1A1 1436/4885KMT2A 1183/4885PTK2B 2787/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 ALDH1A1 3725/4885KMT2A 4752/4885PTK2B 2602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.